Polynovo Limited · ASX:PNV
Polynovo — H1 2025 Earnings Presentation
13 slides from Polynovo's earnings presentation, Feb 24, 2025
Slide 1: 1H25 Results
1H25 Results (in conjunction with Appendix 4D) Accelerating Global Impact 24 February 2025
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by PolyNovo Limited and is provided for general information purposes only. No party other than PolyNovo has authorised or caused the issue of this document, or takes responsibility for, or makes any statements, representations or undertakings in this pr
Slide 3: Transformational Growth: Commercial Sales up 28%, Patients Treated up 72%
Transformational Growth: Commercial Sales up 28%, Patients Treated up 72% 46 Countries U.K. Germany 67,000+ Patients France Turkey Japan Spain China 330+ Independent U.S. Articles and Abstracts* India PMA Status Australia BARDA, FDA Update New Zealand Meaningfully Differentiated Patient Outcomes A$2
Slide 4: 1H25 Financial Results
&B) PolyNovo" 1H25 Financial Results
Slide 5: Sales growth up 28%, Order growth up 58%, Unit growth up 62%
Sales growth up 28%, Order growth up 58%, Unit growth up 62% Product Sales by Region Product Sales: 28.1% NovoSorb BTM and MTX 28.1% 54.9% $54.1 80.0% 54.9% $54.1 70.0% $42.2 CAGR: 67.5% $42.2 60.0% 47.1% 67.5% 50.0% 44.6% $27.3 44.6% $27.3 40.0% 30.0% $16.3 $16.3 $11.3 $11.3 20.0% 5 10.0% 0.0% 1H21
Slide 6: Investing for Growth
Investing for Growth Revenue, opex, NPAT Continued investment in sales growth: Revenue (m) Opex - R&D (m) • Investment in key direct markets 22.8% U.S., U.K, Australia, New Zealand Opex - other (m) and Europe. NLAT/NPAT (m) 65.6% $59.9 • Market development in India. $53.0 $48.8 $5.1 • Clinical and h
Slide 7: Capital Efficient Growth
Capital Efficient Growth Cash flow breakdown Highlights: • A$30.5m cash on hand and cash equivalents $45.9m • Cashflow from operations (A$12.5m): $0.6m o Result impacted by slower U.S. customer ($12.5m) $3.8m $30.5m payments, however significant improvement ($5.1m) in month of Dec 24 and Q3 to date
Slide 8: Geographic Expansion, New Indications, New Products
Geographic Expansion New Indications New Products Anticipated regulatory filing* *U.S. FDA Capacity Expansion Reimbursement support 4 mm Submitted FY24 June 2025: Innovation for PMA and new Centre at PolyNovo HQ U.S. indications Fil (particulate) Q2 FY26 Trauma (U.S.), Hernia Q3 FY26 December 2025:
Slide 9: Next Generation New Standard of Care: Growth and Scaling
Next Generation New Standard of Care 22,205 13,676 Platform technology: 12,649 Graftable & Implantable 7,592 14,690 7,338 8,529 Capital efficient 4,804 2,690 3,863 5,057 Growth and Scaling 2,114 3,475 FY21 FY22 FY23 FY24 FY25 H1 H2 Patients treated 9
Slide 10: Slide 10
Slide 11: 1H25 Financial Results
1H25 Financial Results Highlights: • Revenue up 22.8% • Product sales up 28.1% • Order volume up 58.0% • EBITDA A$7.2m (1H24: A$1.9m) • Net profit after tax A3.3m (1H24: A$2.7m) 11
Slide 12: Appendix: Balance Sheet
Appendix Balance Sheet ($ m) 1 H2 5 FY2 4 Change % Cash and cash equivalent 30.5 45.9 -33.6% Trade and other receivables 28.4 20.7 37.2% Inventories 14.1 9.0 57.4% Other 6.0 3.7 59.9% Tot al current asset s 7 9 .0 7 9 .3 - 0 .5 % Tot al asset s 1 1 2 .7 1 0 8 .8 3 .7 % Tot al liabilit ies 3 7 .2 3 6
Slide 13: Vision, mission and values
Vision, mission and values * NovoSorb® technology platform 13